Eli Lilly and Co
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have […]
Read More
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, […]
Read More
Meta-AMD chip deal, Wall Street’s AI angst, Trump’s State of the Union and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. I found yesterday’s snowfall to be quite idyllic, granted I didn’t actually step foot outside until it had stopped (don’t repeat that to my many colleagues who found themselves on shoveling duty). S&P 500 futures are little changed this morning […]
Read More
Stocks making the biggest moves midday: KKR, Blackstone, CrowdStrike, International Paper & more
Check out the companies making the biggest moves midday: Financials — The financials sector of the S & P 500 slid more than 3% in midday trading, the worst performer in the broad market. Alternative asset managers KKR and Blackstone slid roughly 9% and 7%, respectively, after activist hedge fund Saba Capital Management and Cox […]
Read More
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month’s worth of doses in a single pen. Cash-paying patients can […]
Read More
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino’s Pizza and more
Check out the companies making headlines before the bell. Arcellx — The biotech stock surged 78% after Gilead Sciences said Monday it agreed to acquire Arcellx for $7.8 billion, offering $115 per share in cash at closing and one contingent value right of $5 per share. Arcellx focuses on immunotherapies for patients with cancer and […]
Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s stock […]
Read More
Jim Cramer’s top 10 things to watch in the stock market Friday
My top 10 things to watch Friday, Feb. 20 1. Blue Owl Capital’s loan sales, part of a plan to return capital to investors, has observers bringing out “canary in the coal mine” warnings again. While many private credit loans seem mismarked, this situation doesn’t appear tragic in nature. 2. Stock futures were lower after […]
Read More
Prices, pipelines and patent cliffs: Inside pharma’s big reset
This earnings season, Europe’s biggest pharma companies posted results ranging from 7% beats to 3% misses — but no one really cared. Instead, drugmakers looked ahead, with 2026 shaping up to be a defining year following a dramatic 2025, and one where the impact from last year’s developments is set to crystallize. “2025 was about […]
Read More
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the White House, Nov. 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one — but recent weeks have delivered more […]
Read More